- FASTA Sequence
- PDBx/mmCIF Format
- PDBx/mmCIF Format (gz)
- BinaryCIF Format (gz)
- Legacy PDB Format
- Legacy PDB Format (gz)
- PDBML/XML Format (gz)
- Structure Factors (CIF)
- Structure Factors (CIF - gz)
- Validation Full (PDF - gz)
- Validation (XML - gz)
- Validation (CIF - gz)
- Validation 2fo-fc coefficients (CIF - gz)
- Validation fo-fc coefficients (CIF - gz)
- Biological Assembly 1 (CIF - gz)
- Biological Assembly 1 (PDB - gz)
1Y6B|pdb_00001y6b
Crystal structure of VEGFR2 in complex with a 2-anilino-5-aryl-oxazole inhibitor
- PDB DOI: https://doi.org/10.2210/pdb1Y6B/pdb
- Classification: TRANSFERASE
- Organism(s): Homo sapiens
- Expression System: Escherichia coli
- Mutation(s): No
- Deposited: 2004-12-05 Released: 2005-06-07
- Deposition Author(s): Harris, P.A.,Cheung, M.,Hunter, R.N.,Brown, M.L.,Veal, J.M.,Nolte, R.T.,Wang, L.,Liu, W.,Crosby, R.M.,Johnson, J.H.,Epperly, A.H.,Kumar, R.,Luttrell, D.K.,Stafford, J.A.
Experimental Data Snapshot
- Method: X-RAY DIFFRACTION
- Resolution: 2.10 Å
- R-Value Free: 0.236 (Depositor)
- R-Value Work: 0.192 (Depositor), 0.200 (DCC)
- R-Value Observed: 0.194 (Depositor)
Download MendeleyDiscovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Harris, P.A., Cheung, M., Hunter, R.N., Brown, M.L., Veal, J.M., Nolte, R.T., Wang, L., Liu, W., Crosby, R.M., Johnson, J.H., Epperly, A.H., Kumar, R., Luttrell, D.K., Stafford, J.A.(2005) J Med Chem 48: 1610-1619
- PubMed: 15743202 Search on PubMed
- DOI: https://doi.org/10.1021/jm049538w
- Primary Citation of Related Structures:
1Y6A,1Y6B - PubMed Abstract:
A series of derivatives of 2-anilino-5-phenyloxazole (5) has been identified as inhibitors of VEGFR2 kinase. Herein we describe the structure-activity relationship (SAR) of this novel template. Optimization of both aryl rings led to very potent inhibitors at both the enzymatic and cellular levels. Oxazole 39 had excellent solubility and good oral PK when dosed as the bis-mesylate salt and demonstrated moderate in vivo efficacy against HT29 human colon tumor xenografts. X-ray crystallography confirmed the proposed binding mode, and comparison of oxazoles 39 and 46 revealed interesting differences in orientation of 2-pyridyl and 3-pyridyl rings, respectively, attached at the meta position of the 5-phenyl ring.
- GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA. Philip.A.Harris@gsk.com
Organizational Affiliation:
Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report |Ligand Interaction (AAX)
Global Symmetry: Asymmetric - C1
Global Stoichiometry: Monomer - A1
Find Similar Assemblies
Biological assembly 1 assigned by authors.
Macromolecule Content
- Total Structure Weight: 42.15 kDa
- Atom Count: 2,320
- Modeled Residue Count: 266
- Deposited Residue Count: 366
- Unique protein chains: 1
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| Vascular endothelial growth factor receptor 2 | 366 | Homo sapiens | Mutation(s): 0 Gene Names: KDR, FLK1 EC: 2.7.1.112 (PDB Primary Data), 2.7.10.1 (UniProt) |  | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for P35968 (Homo sapiens) Explore P35968 Go to UniProtKB: P35968 | |||||
PHAROS: P35968 GTEx: ENSG00000128052 | |||||
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | P35968 | ||||
Sequence AnnotationsExpand | |||||
| |||||
| Ligands 1 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
| AAX Query on AAX Download Ideal Coordinates CCD File | B [auth A] | N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE C25 H24 N4 O4 S KRGKAARWVPUWSY-UHFFFAOYSA-N |  | ||
Experimental Data
- Method: X-RAY DIFFRACTION
- Resolution: 2.10 Å
- R-Value Free: 0.236 (Depositor)
- R-Value Work: 0.192 (Depositor), 0.200 (DCC)
- R-Value Observed: 0.194 (Depositor)
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 37.544 | α = 90 |
| b = 94.333 | β = 90 |
| c = 96.767 | γ = 90 |
| Software Name | Purpose |
|---|---|
| REFMAC | refinement |
| MAR345 | data collection |
| SCALEPACK | data scaling |
| AMoRE | phasing |
Deposition Data
- Released Date: 2005-06-07 Deposition Author(s): Harris, P.A.,Cheung, M.,Hunter, R.N.,Brown, M.L.,Veal, J.M.,Nolte, R.T.,Wang, L.,Liu, W.,Crosby, R.M.,Johnson, J.H.,Epperly, A.H.,Kumar, R.,Luttrell, D.K.,Stafford, J.A.
Revision History (Full details and data files)
- Version 1.0: 2005-06-07
Type: Initial release - Version 1.1: 2008-04-30
Changes: Version format compliance - Version 1.2: 2011-07-13
Changes: Advisory, Version format compliance - Version 1.3: 2017-10-11
Changes: Refinement description - Version 1.4: 2024-02-14
Changes: Data collection, Database references, Derived calculations
- RCSB PDB is hosted by
- RCSB PDB is a member of
- RCSB Partners
- Nucleic Acid Knowledgebase
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.